ESMO 2018 | Denosumab for NSCLC: results from SPLENDOUR
Solange Peters
Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, gives us an update on the ETOP and EORTC SPLENDOUR trial (NCT02129699) of denosumab for advanced non-small cell lung cancer.
Related videos
2:07
Clinical updates on ALK inhibitor treatment strategies for NSCLC
Frank Griesinger
2:14
Updates on the CRISP study
Frank Griesinger
1:44
Targeting hypoxia in tumors with combination therapy
Kaye Williams
1:11
Hypoxia in the tumor microenvironment drives radiation resistance
Kaye Williams
3:07
Future uses of ctDNA measurements: changing the treatment landscape
Pierre-Jean Lamy
